Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for Up to 3 Years From the ASSURE Study.
出版信息
Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 12):8-9.
Abstract
摘要
相似文献
1
Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for Up to 3 Years From the ASSURE Study.开放标签的塞拉德尔帕治疗原发性胆汁性胆管炎患者的长期疗效和安全性：ASSURE研究长达3年的汇总中期结果
Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 12):8-9.
2
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.一项在原发性胆汁性胆管炎患者中进行的 II 期、随机、开放标签、52 周研究，评估 seladelpar 的疗效。
J Hepatol. 2022 Aug;77(2):353-364. doi: 10.1016/j.jhep.2022.02.033. Epub 2022 Mar 30.
3
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.开放标签、临床试验扩展：seladelpar 治疗原发性胆汁性胆管炎患者的两年安全性和疗效结果。
Aliment Pharmacol Ther. 2024 Jan;59(2):186-200. doi: 10.1111/apt.17755. Epub 2023 Oct 30.
4
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC).塞拉莱德帕：一种用于治疗早期原发性胆汁性胆管炎 (PBC) 的在研药物。
Expert Opin Investig Drugs. 2022 Oct;31(10):1101-1107. doi: 10.1080/13543784.2022.2130750. Epub 2022 Oct 8.
5
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.原发性胆汁性胆管炎患者奥贝胆酸的长期疗效和安全性：一项国际开放标签扩展研究的 3 年结果。
Lancet Gastroenterol Hepatol. 2019 Jun;4(6):445-453. doi: 10.1016/S2468-1253(19)30094-9. Epub 2019 Mar 26.
6
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.原发性胆汁性胆管炎患者在 3 个月时的塞拉莱德帕疗效和安全性：一项 3 期、随机、安慰剂对照研究（ENHANCE）。
Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6.
7
The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis.塞拉达帕在原发性胆汁性胆管炎中的作用：一项系统评价和荟萃分析。
BMC Gastroenterol. 2025 Apr 5;25(1):224. doi: 10.1186/s12876-025-03812-3.
8
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.塞拉得帕（MBX-8025），一种选择性过氧化物酶体增殖物激活受体 δ 激动剂，用于治疗对熊去氧胆酸应答不足的原发性胆汁性胆管炎患者：一项双盲、随机、安慰剂对照、2 期、概念验证研究。
Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726. doi: 10.1016/S2468-1253(17)30246-7. Epub 2017 Aug 14.
9
Seladelpar for the Treatment of Primary Biliary Cholangitis.塞拉达帕用于治疗原发性胆汁性胆管炎。
Ann Pharmacother. 2025 Mar 12:10600280251320069. doi: 10.1177/10600280251320069.
10
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis.评估 seladelpar 治疗原发性胆汁性胆管炎成人患者的安全性和疗效。
Expert Opin Pharmacother. 2024 Aug;25(11):1517-1523. doi: 10.1080/14656566.2024.2390120. Epub 2024 Aug 11.
引用本文的文献
1
Evolving therapeutic landscape of primary biliary cholangitis: A review.原发性胆汁性胆管炎不断演变的治疗前景：综述
World J Hepatol. 2025 Jul 27;17(7):107223. doi: 10.4254/wjh.v17.i7.107223.
Zotero 插件